COVAX & Team Europe ‘Not Structural Solutions’ To COVID-19 Vaccine Inequity
The medicines access organization, WEMOS, says that COVAX and “Team Europe” are welcome initiatives but they do not address the longer-term issues involved in making countries more self-sufficient in COVID-19 vaccine manufacturing. The organization has set up a website to analyze the various initiatives under way to make vaccines available to less wealthy countries.
You may also be interested in...
Numerous initiatives are under way to maximize equitable access to COVID-19 products around the world, but most have some drawbacks that need to be addressed if they are to meet their goals, according to the medicines access NGO, WEMOS.
The members of a new group aiming to boost rare disease R&D say that Europe needs a “solid pro-innovation ecosystem” supported by a stable intellectual property framework and a “world-class” regulatory system.
A World Health Organization negotiating body has agreed to develop a “zero draft” of the proposed pandemic treaty for discussion at a meeting of WHO member states in February next year. But the international pharmaceutical industry has reiterated its concerns about some of the proposals being put forward.